Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has earned an average recommendation of “Buy” from the thirteen ratings firms that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $51.90.

A number of research analysts recently commented on the stock. Berenberg Bank assumed coverage on shares of Supernus Pharmaceuticals in a research report on Thursday, February 1st. They set a “buy” rating and a $66.00 price objective on the stock. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 1st. B. Riley reaffirmed a “buy” rating and set a $54.00 price objective on shares of Supernus Pharmaceuticals in a research report on Thursday, January 18th. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. Finally, Janney Montgomery Scott upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Monday, December 4th.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $48.04, for a total value of $960,800.00. Following the completion of the sale, the vice president now directly owns 32,500 shares in the company, valued at $1,561,300. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Victor Vaughn sold 5,750 shares of the business’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $45.03, for a total transaction of $258,922.50. Following the completion of the sale, the vice president now owns 15,094 shares of the company’s stock, valued at $679,682.82. The disclosure for this sale can be found here. Insiders sold 165,750 shares of company stock valued at $7,133,973 over the last quarter. Corporate insiders own 6.70% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Advisor Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 13.7% in the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after buying an additional 410 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter worth $188,000. Balyasny Asset Management LLC acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $206,000. M&T Bank Corp acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $213,000. Finally, Shelton Capital Management acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $215,000. Institutional investors and hedge funds own 98.20% of the company’s stock.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) traded up $1.45 on Tuesday, reaching $38.65. 433,100 shares of the company were exchanged, compared to its average volume of 757,894. Supernus Pharmaceuticals has a 52-week low of $24.65 and a 52-week high of $50.04. The stock has a market capitalization of $1,960.00, a P/E ratio of 35.14 and a beta of 1.08.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm had revenue of $80.40 million for the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals’s revenue was up 41.5% compared to the same quarter last year. equities research analysts forecast that Supernus Pharmaceuticals will post 1.07 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://theolympiareport.com/2018/02/13/supernus-pharmaceuticals-inc-supn-receives-average-rating-of-buy-from-brokerages.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.